Clinical trial · no report yet · Phase 2
DPT02
A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors
- NCT04482309 ↗
- Active not recruiting
- AstraZeneca
- 196 commentary sources found
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| YouTube | 66 | |
| X threads | 65 | |
| Podcasts | 64 | |
| X videos | 1 |
The trial
ClinicalTrials.gov- Official title
- A Phase 2, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Trastuzumab Deruxtecan (T-DXd, DS-8201a) for the Treatment of Selected HER2 Expressing Tumors (DESTINY-PanTumor02)
- Phase
- Phase 2
- Status
- Active not recruiting
- Conditions
- Part 1: Bladder, Biliary Tract, Cervical, Endometrial, Ovarian, Pancreatic Cancer, Rare Tumors, Any Tumor Type Excluding Breast, Gastric, Colorectal Cancer; Part 2: HER2 Expressing/Amplified Solid Tumors Excluding Breast, Gastric, Colorectal Cancer
- Interventions
- Trastuzumab deruxtecan
- Arms
- Part 1 Cohort 1 · Experimental
- Part 1 Cohort 2 · Experimental
- Part 1 Cohort 3 · Experimental
- Part 1 Cohort 4 · Experimental
- Part 1 Cohort 5 · Experimental
- Part 1 Cohort 6 · Experimental
- Part 1 Cohort 7 · Experimental
- Part 2 Cohort A · Experimental
- Part 2 Cohort B · Experimental
- Part 2 Cohort C · Experimental
- Part 2 Cohort D · Experimental
- Part 2 Cohort E · Experimental
- Enrollment
- 477
- Primary outcomes
- Objective Response Rate (ORR)
- Sponsor
- AstraZeneca with Daiichi Sankyo Co., Ltd.
- Start
- Aug 18, 2020
- Primary completion
- Mar 23, 2027 (estimated)
- Results posted
- No
- Registry record
- NCT04482309 · updated Jul 10, 2026
Publications
linked from the registry- Lee JY, Oaknin A, Manso L, Gonzalez-Martin A, Lugowska I, Lorusso D, Banerjee S, Liao JB, Lu CH, Prasongsook N, Melichar B, Anoka C, Jung L, Michelini F, Puvvada S, Meric-Bernstam F, Makker V. Trastuzumab deruxtecan in HER2-expressing gynecologic cancers from DESTINY-PanTumor02: antitumor activity, safety, and exploratory biomarker analyses. J Gynecol Oncol. 2026 May;37(3):e65. doi: 10.3802/jgo.2026.37.e65. Epub 2026 May 6. PubMed 42135959
- Oaknin A, Lee JY, Makker V, Oh DY, Banerjee S, Gonzalez-Martin A, Jung KH, Lugowska I, Manso L, Manzano A, Melichar B, Siena S, Stroyakovskiy D, Fielding A, Puvvada S, Smith A, Meric-Bernstam F. Efficacy of Trastuzumab Deruxtecan in HER2-Expressing Solid Tumors by Enrollment HER2 IHC Status: Post Hoc Analysis of DESTINY-PanTumor02. Adv Ther. 2024 Nov;41(11):4125-4139. doi: 10.1007/s12325-024-02975-x. Epub 2024 Sep 11. PubMed 39261417
- Meric-Bernstam F, Makker V, Oaknin A, Oh DY, Banerjee S, Gonzalez-Martin A, Jung KH, Lugowska I, Manso L, Manzano A, Melichar B, Siena S, Stroyakovskiy D, Fielding A, Ma Y, Puvvada S, Shire N, Lee JY. Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial. J Clin Oncol. 2024 Jan 1;42(1):47-58. doi: 10.1200/JCO.23.02005. Epub 2023 Oct 23. PubMed 37870536